# Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

> **NCT01031953** · PHASE1,PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 34 (actual)

## Conditions studied

- Breakthrough Nausea and Vomiting
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** fosaprepitant dimeglumine
- **DRUG:** systemic chemotherapy
- **OTHER:** survey administration
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT01031953
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Drug contract timelines and inadequate enrollment
- **Last updated:** 2017-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031953, "Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01031953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*